The deal includes access to funding that could support various activities, including funding studies necessary to support an FDA submission and accelerate commercial scale up to facilitate potential adoption by U.S. blood centers.

The INTERCEPT Blood System is a pathogen reduction technology designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, parasites, and leukocytes that may be present in donated blood.

Pathogen reduction treatment of blood components offers the opportunity to improve national emergency preparedness for epidemic and endemic blood-borne pathogens such as Zika, dengue, and chikungunya, and to further protect patients undergoing routine care, especially in regions with rapidly emerging epidemic pathogens.

Cerus will receive initial funding of up to $30,750,939 to support activities related to a clinical trial to assess the safety and efficacy of INTERCEPT RBCs compared to conventional RBCs in Puerto Rico, a region impacted by the current Zika virus epidemic.

This funding also will support activities related to in vitro studies to facilitate potential pivotal Phase III clinical trials in the continental U.S.

The five-year contract with BARDA includes a base period with committed funding of up to $30,750,939, and subsequent option periods that, if exercised by BARDA and completed, would bring the total non-dilutive funding opportunity to up to $180,509,914 over the five-year contract period.

If exercised by BARDA, the subsequent options would fund activities related to broader implementation in areas of Zika virus risk, clinical and regulatory development programs in support of licensure, and development, manufacturing and scale-up activities. Related to manufacturing, Cerus and its partners will be responsible for co-investment in the amount of $14.5 million.

In addition, the BARDA contract also includes the possibility of funding the deployment of previously licensed INTERCEPT-treated platelet and plasma components for use in Hawaii to support self-sufficiency of that region in the event of an active Zika outbreak.

INTERCEPT pathogen reduction technology for platelets and plasma has been used in Europe for over 10 years as a safety measure to reduce the risk of transfusion-transmitted infections in platelet and plasma components, and was in routine use in French Polynesia and the French West Indies during the Zika outbreak in 2013-2014.

Cerus received FDA approvals for the INTERCEPT Blood System for platelets and plasma in December 2014, and the system is now in routine use in a number of blood centers across the United States. INTERCEPT was approved for platelets and plasma in Brazil in December 2015.

"This contract offers the potential to fund activities related to anticipated Phase III clinical studies for the INTERCEPT Red Blood Cell System in the United States and the required manufacturing and development activities needed to pursue a potential U.S. commercial launch," said Dr. Laurence Corash, Cerus’ chief scientific officer.

"We believe that T-cell inactivation levels with INTERCEPT provide the opportunity for future replacement of gamma irradiation, which would also align with the Department of Homeland Security’s initiative to eliminate nuclear source irradiators in the U.S. through the introduction of non-nuclear technologies."

Both the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO) have issued guidance documents that acknowledge the risk of Zika virus transmission via blood transfusion and have identified the use of pathogen reduction technology as an appropriate blood safety measure to reduce transfusion risks.

Cerus reported positive results of the INTERCEPT Red Blood Cell System from a European Phase III clinical trial in January 2015, and also from a U.S. Phase II clinical trial in December 2014. The Company plans to submit an application for CE Mark registration of INTERCEPT RBCs in the second half of 2016.